The David H. Koch Institute for Integrative Cancer Research at MITThe David H. Koch Institute for Integrative Cancer Research at MIT

Massachusetts Institute of Technology

National Cancer Institute Cancer Center

Science + Engineering... Conquering Cancer Together

Resistance is Brutal

Chemotherapy induces damage in both cancer and normal cells, and it is increasingly clear that the non-cancerous cells in the tumor can contribute to the development of therapeutic resistance. Building on previous work in this area, researchers in the laboratory of KI faculty member Michael Hemann, have discovered that doxorubicin, a common chemotherapeutic agent, induces a previously uncharacterized response in endothelial cells (the cells lining the blood vessels). This response, termed “acute stress-associate phenotype” or “ASAP” can promote chemoresistance in B-cell lymphoma through the activation of a signaling pathway affecting inflammation and cytokine secretion. Their results, published in Genes & Development, emphasize the importance of studying not just cancer cells themselves, but also the tumor microenvironment in order to develop targeted treatments to suppress such resistance mechanisms. Read article